NO961113L - Behandling og forebyggelse av prostatakreft - Google Patents
Behandling og forebyggelse av prostatakreftInfo
- Publication number
- NO961113L NO961113L NO961113A NO961113A NO961113L NO 961113 L NO961113 L NO 961113L NO 961113 A NO961113 A NO 961113A NO 961113 A NO961113 A NO 961113A NO 961113 L NO961113 L NO 961113L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen
- prostate cancer
- ethyl
- absent
- halogen
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- YEXWPTQVHNJMNW-UHFFFAOYSA-N 2h-benzo[h]quinolin-3-one Chemical class C1=CC=C2C=CC3=CC(=O)CN=C3C2=C1 YEXWPTQVHNJMNW-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/407,822 US5635197A (en) | 1995-03-21 | 1995-03-21 | Treatment and prevention of prostatic cancer metastasis |
| US08/408,745 US5629007A (en) | 1995-03-21 | 1995-03-21 | Method of preventing prostatic cancer development |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO961113D0 NO961113D0 (no) | 1996-03-19 |
| NO961113L true NO961113L (no) | 1996-09-23 |
Family
ID=27020024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961113A NO961113L (no) | 1995-03-21 | 1996-03-19 | Behandling og forebyggelse av prostatakreft |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0733365A3 (cs) |
| JP (1) | JPH08277220A (cs) |
| KR (1) | KR960034202A (cs) |
| AU (1) | AU695860B2 (cs) |
| CA (1) | CA2172211A1 (cs) |
| CZ (1) | CZ287977B6 (cs) |
| HU (1) | HUP9600702A3 (cs) |
| IL (1) | IL117537A (cs) |
| MX (1) | MX9601031A (cs) |
| NO (1) | NO961113L (cs) |
| SG (1) | SG47093A1 (cs) |
| TW (1) | TW450809B (cs) |
| YU (1) | YU16196A (cs) |
| ZA (1) | ZA962141B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| CA2270433A1 (en) * | 1996-10-30 | 1998-05-07 | Eli Lilly And Company | Synthesis of benzo¬f|quinolinones |
| US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
| CA2338298A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Tricyclic compounds |
| US6436489B1 (en) | 1999-03-24 | 2002-08-20 | Clariant International Ltd. | Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures |
| RU2153358C1 (ru) * | 1999-11-10 | 2000-07-27 | Центральный научно-исследовательский рентгенорадиологический институт МЗ России | Способ лечения остеолитических метастазов |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5239075A (en) * | 1991-08-21 | 1993-08-24 | Eli Lilly And Company | Process for the preparation of benzo (f) quinolinones |
| ES2169026T3 (es) * | 1991-08-21 | 2002-07-01 | Lilly Co Eli | Benzo(f)quinolinonas como inhibidores de 5-alfa-reductasa. |
-
1996
- 1996-03-15 TW TW085103095A patent/TW450809B/zh active
- 1996-03-15 SG SG1996006549A patent/SG47093A1/en unknown
- 1996-03-15 ZA ZA9602141A patent/ZA962141B/xx unknown
- 1996-03-18 IL IL11753796A patent/IL117537A/xx not_active IP Right Cessation
- 1996-03-19 EP EP96301846A patent/EP0733365A3/en not_active Withdrawn
- 1996-03-19 AU AU48168/96A patent/AU695860B2/en not_active Ceased
- 1996-03-19 NO NO961113A patent/NO961113L/no not_active Application Discontinuation
- 1996-03-19 YU YU16196A patent/YU16196A/sh unknown
- 1996-03-19 CZ CZ1996825A patent/CZ287977B6/cs unknown
- 1996-03-19 KR KR1019960007405A patent/KR960034202A/ko not_active Ceased
- 1996-03-19 MX MX9601031A patent/MX9601031A/es not_active IP Right Cessation
- 1996-03-20 CA CA002172211A patent/CA2172211A1/en not_active Abandoned
- 1996-03-20 HU HU9600702A patent/HUP9600702A3/hu unknown
- 1996-03-21 JP JP8064428A patent/JPH08277220A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CZ287977B6 (cs) | 2001-03-14 |
| IL117537A0 (en) | 1996-07-23 |
| HU9600702D0 (en) | 1996-05-28 |
| EP0733365A2 (en) | 1996-09-25 |
| CA2172211A1 (en) | 1996-09-22 |
| EP0733365A3 (en) | 1997-03-05 |
| MX9601031A (es) | 1997-02-28 |
| SG47093A1 (en) | 1998-03-20 |
| TW450809B (en) | 2001-08-21 |
| AU4816896A (en) | 1996-10-03 |
| KR960034202A (ko) | 1996-10-22 |
| JPH08277220A (ja) | 1996-10-22 |
| AU695860B2 (en) | 1998-08-27 |
| YU16196A (sh) | 1998-11-05 |
| NO961113D0 (no) | 1996-03-19 |
| ZA962141B (en) | 1997-09-15 |
| IL117537A (en) | 2001-01-11 |
| HUP9600702A2 (en) | 1996-12-30 |
| CZ82596A3 (en) | 1996-10-16 |
| HUP9600702A3 (en) | 1997-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199901653T2 (xx) | Fitalazinonlar. | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| DE69433984D1 (de) | Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d | |
| MY157373A (en) | Carbamate compounds for use in preventing or treating movement disorders | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| AU2492500A (en) | Aspartic protease inhibitors, compositions, and associated therapeutic methods | |
| FR2699918B1 (fr) | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. | |
| NO961113L (no) | Behandling og forebyggelse av prostatakreft | |
| DE69833797D1 (de) | Substituierte 2-benzylamino-2-phenyl-acetamidverbindungen | |
| ZA982137B (en) | Cycloalkylalkanecarboxamides and their preparation and use. | |
| DE60210976D1 (de) | Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung | |
| DE60210960D1 (de) | Carbamat-verbindungen zur prävention oder behandlung von angstzuständen | |
| DE60202669D1 (de) | 6-phenylbenzonaphthyidine | |
| DE60105618D1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
| TR200001926T2 (tr) | Vasküler başağrılarına karşı lokal anesteziklerin yeni kullanımı | |
| BG104037A (en) | 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy | |
| DE69916577D1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
| NO20040176L (no) | Karbamatforbindelser for anvendelse ved prevensjon eller terapi av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte | |
| MY136347A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| CY1115764T1 (el) | Αναστολεις iap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |